Valuation: Patrys Limited

Market Cap 13.39M 9.03M 8.2M 7.57M 6.83M 12.9M 844M 91.25M 36.09M 455M 33.88M 33.17M 1.44B P/E 2025
-0.68x
P/E 2026 -4.22x
Enterprise Value 10.03M 6.76M 6.14M 5.67M 5.12M 9.66M 632M 68.35M 27.04M 341M 25.38M 24.85M 1.08B EV / Sales 2025
1.96x
EV / Sales 2026 2,223x
Free-Float
72.81%
Yield 2025 *
-
Yield 2026 -
Current month-4.17%
1 month-14.81%
3 months-28.12%
6 months-25.81%
Current year-17.86%
1 week 0.02
Extreme 0.022
0.02
1 month 0.02
Extreme 0.02
0.03
Current year 0.02
Extreme 0.02
0.05
1 year 0.02
Extreme 0.02
0.05
3 years 0.01
Extreme 0.011987
0.12
5 years 0.01
Extreme 0.011987
0.54
10 years 0.01
Extreme 0.011987
0.91
Manager TitleAgeSince
Chief Executive Officer - 2026-02-15
Corporate Secretary - 2025-11-09
Corporate Secretary - 2025-11-09
Director TitleAgeSince
Director/Board Member - 2025-06-16
Chairman 64 -
Director/Board Member - 2025-11-09
Date Insider Type Main position Quantity % Market Cap. Importance
8/11/23 Expiration

Chief Executive Officer

396,132 0.0193%
8/11/23 Expiration

Chief Executive Officer

3,283 0.0002%
12/6/21 Buy

Chief Executive Officer

1,337,164 0.0675%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-37.84%-76.04% 9.03M
+1.15%-2.81%+55.79%+71.12% 66.37B
-2.64%-1.13%+7.82%+88.90% 58.86B
-1.07%+0.30%+22.91%+86.76% 55.22B
+0.48%-2.53%+9.73%+121.14% 47.21B
-2.69%-6.38%+19.19%+25.79% 42.45B
-0.70%+4.93%+17.77%+45.03% 36.44B
-2.50%-15.73%+135.31%+662.73% 35.19B
-0.77%-2.21%+77.27%+57.96% 32.66B
-0.83%+1.98%-38.27%+390.98% 26.73B
Average -0.96%-0.31%+26.97%+147.44% 40B
Weighted average by Cap. -0.97%-2.18%+33.93%+146.74%

Financials

2025 2026
Net sales 829K 559K 507K 469K 423K 798K 52.2M 5.65M 2.23M 28.17M 2.1M 2.05M 89M 8.98K 6.06K 5.5K 5.08K 4.58K 8.65K 566K 61.23K 24.22K 305K 22.73K 22.25K 965K
Net income -3.01M -2.03M -1.84M -1.7M -1.54M -2.9M -190M -20.53M -8.12M -102M -7.62M -7.46M -324M -3.42M -2.3M -2.09M -1.93M -1.74M -3.29M -215M -23.27M -9.21M -116M -8.64M -8.46M -367M
Net Debt -742K -501K -455K -420K -379K -715K -46.78M -5.06M -2M -25.24M -1.88M -1.84M -79.75M -3.36M -2.27M -2.06M -1.9M -1.71M -3.24M -212M -22.9M -9.06M -114M -8.5M -8.32M -361M
Projected Income Statement - Annual - Patrys Limited
Logo Patrys Limited
Patrys Limited is an Australia-based company. The Company is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody. PAT-DX1 is a dimer of a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10. PAT-DX3 is a humanized, full-sized antibody that has been further optimized to improve its therapeutic potential. It is also focused on developing RLS-2201, a proprietary injectable formulation of quetiapine.
Employees
10
Date Price Change Volume
26-11-18 A$0.0230 0.00% 102,990
26-11-17 A$0.0230 -2.13% 67,179
26-11-16 A$0.0235 +2.17% 9,493
26-11-13 A$0.0230 0.00% 239,300
26-11-12 A$0.0230 0.00% 96,017